Overview

CONSHOHOCKEN, Pa. , May 07, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2020 financial results and highlights: “Madrigal continued to make progress toward our clinical development and business objectives during the first quarter of 2020,

-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety and trial integrity during the COVID pandemic. PDFF vs NASH resolution (ROC) PRO-C3/C3M ratio

CONSHOHOCKEN, Pa. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: “Madrigal made significant progress during 2019 in executing our business strategy and advancing the development